A Phase II, Multicentre, Pilot, Randomised, Double Blind Placebo Controlled Dose Titration Study to Evaluate the Safety, Maximum Tolerated Dose and Preliminary Evidence of Efficacy of Orally Administered Ralfinamide at Four Doses (80, 160, 240 and 320 mg/Day) in Patients With Neuropathic Pain

Trial Profile

A Phase II, Multicentre, Pilot, Randomised, Double Blind Placebo Controlled Dose Titration Study to Evaluate the Safety, Maximum Tolerated Dose and Preliminary Evidence of Efficacy of Orally Administered Ralfinamide at Four Doses (80, 160, 240 and 320 mg/Day) in Patients With Neuropathic Pain

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Ralfinamide (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Newron Pharmaceuticals; Newron Sweden AB
  • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2004-000557-35).
    • 14 Aug 2008 New source identified and integrated (ClinicalTrials.gov record NCT0000736151).
    • 16 Apr 2008 Primary endpoint `pain intensity' achieved; according to a Newron Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top